Samuel Z Goldhaber, MD
Professor of Medicine
Harvard Medical School
Director, Venous Thromboembolism Research Group
Co-Director, Anticoagulation Management Service
Cardiovascular Division
Brigham and Women's Hospital
Boston, MA
Clotblog with Dr Samuel Goldhaber
View all posts »AMPLIFY-Extension: What to do with PE and DVT patients after the initial period of anticoagulation
Dec 14, 2012 11:25 EST-
0Comments
-
Read later
The exciting results of the AMPLIFY-Extension trial, just released at the American Society of Hematology meeting, show the efficacy of apixaban—with lower bleeding rates than placebo—for the treatment of PE and DVT in patients following an initial six- to 12-month period of standard anticoagulation.
Will you plan to extend anticoagulation to this patient set based on this study?
See also:
AMPLIFY-EXT: Extra year of apixaban safely cuts long-term recurrent-VTE risk
You must be a member (with full membership) to post a comment.
Already a member?
Enjoy all the benefits of theheart.org
With full membership, you can check out our educational and editorial content, search the site, receive our newsletters, join discussions, download slides and much more.
Membership is free!
